Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting

✍ Scribed by Byungsu Kim; Eui Yul Choi; Chang Yoon Kim; Kyuyung Song; Yeon Ho Joo

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 99 KB
• Volume: 23
• Category: Article
• ISSN: 0885-6222
• DOI: 10.1002/hup.897

✦ Synopsis

Abstract

Objective

This study seeks to replicate previous results indicating that T102C in the serotonin 2A receptor (HTR2A) and Ser9Gly in the dopamine D3 receptor (DRD3) were associated with a risperidone response to acutely exacerbated schizophrenia, and to determine whether possession of these alleles predicts clinical improvement in a naturalistic setting.

Methods

We consecutively recruited 100 schizophrenia patients and assessed clinical improvement after 4 weeks of risperidone treatment.

Results

The patients with T/T in the HTR2A gene showed less clinical improvement than did those with T/C or C/C (p = 0.044). In the case of the DRD3 gene, we did not find statically significant association with clinical improvement (p = 0.061). When patients were categorized into responders and nonresponders, the C allele was more frequent in responders (OR = 2.28, 95%CI = 1.06–4.91, p = 0.039). When combinations of the two polymorphisms were considered, patients who had T/T in the HTR2A gene and encoded Ser/Ser or Ser/Gly from DRD3 gene had a higher propensity to non‐responsiveness compared to other subjects (OR = 3.57, 95%CI = 1.10–11.62, p = 0.039).

Conclusions

Our findings suggest that the HTR2A T102C could be a potential indicator of clinical improvement after risperidone treatment. Copyright © 2007 John Wiley & Sons, Ltd.